New York, Jan 17, 2026, 15:44 ET — Market closed.
- Thermo Fisher (TMO) edged down 0.95% Friday, closing at $618.72.
- U.S. stock and bond markets will be closed Monday in observance of Martin Luther King Jr. Day, with trading set to resume Tuesday.
- Thermo Fisher Scientific is set to release its fourth-quarter and full-year 2025 earnings on Jan. 29, before the market opens.
Shares of Thermo Fisher Scientific Inc slipped Friday, surrendering early gains after hitting just below $630. The stock finished at $618.72, down 0.95%, with trading ranging from $618.71 to $629.73, per Investing.com data.
The drop is significant given the next U.S. equity session won’t come until Tuesday. Markets are closed Monday for Martin Luther King Jr. Day, narrowing the timeframe for investors to adjust positions after Friday’s close.
Thermo Fisher faces its next major checkpoint on Jan. 29, with results and an earnings call set for 8:30 a.m. ET. Investors will watch closely for updates on guidance and demand trends, particularly in lab tools and contract drug development.
Friday saw a quiet slide. The S&P 500 and Nasdaq each slipped roughly 0.1% as the first earnings week on Wall Street wrapped up.
The broader life-science tools sector took a hit as well. Agilent tumbled 3.58%, Danaher dipped 1.63%, and Thermo Fisher slipped 0.95% on the same day, according to MarketWatch data.
Despite Friday’s dip, Thermo Fisher remains near its 52-week peak. According to Macrotrends, the stock’s range over the past year spans from $385.46 up to $629.87.
Analysts remained mostly upbeat behind the scenes. A note from Zacks on Friday highlighted Thermo Fisher’s recent acquisitions and its push to integrate OpenAI tech into its offerings. But it also flagged leverage and currency risks to keep an eye on.
Thermo Fisher has embraced that narrative. In an October announcement about its OpenAI partnership, CEO Marc Casper declared, “AI is shaping the future of science.” Thermo Fisher Scientific Investors
The company has also expanded its portfolio through M&A. In September, Thermo Fisher completed the purchase of Solventum’s Purification & Filtration business for about $4.0 billion in cash. The business is projected to bring in roughly $750 million in revenue by 2025.
Thermo Fisher is eyeing another deal for 2026. Back in October, the company announced plans to acquire clinical services provider Clario for as much as $9.4 billion. The deal is slated to wrap up in early 2026.
That said, the setup isn’t foolproof. A margin miss, a slowdown in customer spending, or a conservative 2026 outlook could weigh on a stock currently trading close to its peak and known for sharp swings post-earnings.
Investors will turn their attention back on Tuesday, when trading resumes after the U.S. holiday, with the Jan. 29 earnings report set to drop before the bell.
Related articles: NYSE:TMO
